HCM
AQST icon

Harvey Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Harvey Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-343,755
Closed -$1.92M – 79
2025
Q3 		$1.92M Buy
343,755
+10,000
+3% +$43.2K 0.41% 48
2025
Q2 		$1.13M Sell
333,755
-165,815
-33% -$476K 0.27% 51
2025
Q1 		$1.45M Buy
499,570
+232,180
+87% +$703K 0.38% 49
2024
Q4 		$952K Buy
267,390
+249,790
+1,419% +$1.15M 0.22% 54
2024
Q3 		$87.6K Buy
+17,600
New +$68.5K 0.02% 75

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harvey Capital Management's AQST Position: Q4 2025 in Review

Harvey Capital Management sold out of Aquestive Therapeutics (AQST) in Q4 2025, closing a stake of 343,755 shares — an estimated $1.92M sold.

Harvey Capital Management first reported a position in AQST in Q3 2024 and held it in 5 quarters. The position peaked at $1.92M in Q3 2025. 177 funds tracked by Wall St. Rank hold AQST as of Q4 2025.

  • Harvey Capital Management reported no remaining Aquestive Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Harvey Capital Management sold 343,755 Aquestive Therapeutics shares in Q4 2025, an estimated $1.92M.
  • Harvey Capital Management first reported a position in Aquestive Therapeutics in Q3 2024 and held it in 5 quarters.
  • Harvey Capital Management's Aquestive Therapeutics position peaked at $1.92M in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2025.

Based on Harvey Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.